WHO advises against drugs and surgery for obesity in under-10s
The first WHO guidelines on childhood obesity put comprehensive support first and limit medication and surgery to adolescents, under conditions.
The World Health Organization (WHO) released its first global guidelines on obesity in children and adolescents on Oct. 7, 2026. For children under 10, the organization does not recommend drug treatment, bariatric surgery or weight-loss devices.
Instead, it proposes structured eating programs, physical activity programs and behavior-change programs, used separately or together. Digital tools get a conditional recommendation, with parental supervision.
For ages 10 to 19, the adolescent guideline keeps those same interventions. It allows an approved medication to be considered, under conditions, if a supervised multicomponent program did not work, and bariatric surgery only for severe obesity with strict requirements.
"The foundation of obesity care for children and adolescents is not medicine or surgery, but access to comprehensive support."
That is the position of Dr. Luz María De Regil, WHO's director of Nutrition and Food Safety, according to the organization's statement. The guidelines also call for addressing mental health and stigma, because anxiety and depression influence the behaviors of affected children.
On the caution about drugs, Infosalus, a Spanish health news outlet, reports that WHO's Dr. María Nieves García Casal explained that, because children are still growing, an intervention may look successful today and have unknown future consequences. The drugs in question include GLP-1 receptor agonists, medicines for diabetes and obesity.
What the documents are
They are not a study with their own sample. They are clinical guidelines built from systematic evidence reviews that weigh benefits, harms, equity, feasibility and costs. The guideline for children covers ages 29 days to under 10 and runs 120 pages; the adolescent one runs 133. The number of studies included and the certainty of the evidence for each recommendation are in the full texts, which this outlet has not reviewed.
The size of the problem
According to WHO, 170 million children and adolescents aged 5 to 19 were living with obesity in 2024. Of them, 70 million were aged 5 to 9 and 100 million were 10 to 19. Prevalence in that group rose from 2% to 8% since 1990. These are global figures, not Mexico's; the Mexican ones from the 2023 Ensanut Continua are in our Oct. 5 report (in Spanish).
The exact length of prior program the guideline requires before a medication is considered, and the definition of severe obesity, remain unconfirmed. There is also no reaction yet from Mexico's Health Ministry or the IMSS.
These are recommendations for health systems and clinical staff, aimed at children under 10 and adolescents aged 10 to 19; they do not apply to adults and are not individual medical advice. Any treatment decision belongs to the treating physician, and this report does not replace a consultation.
